On November 6, 2024 HUTCHMED (China) Limited ("HUTCHMED") (Nasdaq/AIM:HCM; HKEX:13) reported that new and updated data from the sovleplenib ESLIM-01 Phase III trial, as well as several investigator-initiated studies of compounds discovered by HUTCHMED will be presented at the American Society of Hematology (ASH) (Free ASH Whitepaper) ("ASH") Annual Meeting taking place on December 7-10, 2024 in San Diego, USA, and the European Society for Medical Oncology ("ESMO") Asia Congress 2024, taking place on December 6-8, 2024 in Singapore (Press release, Hutchison China MediTech, NOV 6, 2024, View Source [SID1234647816]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Long-term safety and efficacy data from a follow-on, open-label sub-study of the extension stage of ESLIM-01 Phase III study of sovleplenib in adult patients with chronic primary immune thrombocytopenia ("ITP") in China will be reported at the 2024 ASH (Free ASH Whitepaper) Annual Meeting (NCT05029635). At data cut-off on January 31, 2024, a total of 179 patients were treated with at least one dose of sovleplenib. 55.3% (99/179) of the patients were still on the treatment in the sub-study, with a median duration of exposure of 56.6 weeks.
The follow-on sub-study data demonstrated that long-term treatment with sovleplenib was effective in increasing and maintaining platelet count in adults with chronic primary ITP in China. In the overall population, the overall response was achieved by 81% (145/179) of the patients, with a durable response rate of 51.4% and long-term durable response rate of 59.8%. The median cumulative duration of platelet count ≥50×10⁹/L was 38.9 weeks. The long-term treatment was well tolerated, with a safety profile consistent with previous studies and no new safety signals were identified.
Abstract title
Presenter / Lead author
Presentation details
2024 ASH (Free ASH Whitepaper) ANNUAL MEETING – SPONSORED STUDY
Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China
Yu Hu
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
#2558
Disorders of Platelet Number or Function: Clinical and Epidemiological: Poster II
Sunday, December 8, 2024
6:00 PM – 8:00 PM Pacific Time
ESMO ASIA CONGRESS 2024 – INVESTIGATOR-INITIATED STUDIES
Efficacy and safety of fruquintinib combined with serplulimab as 1st line treatment in advanced non-clear cell renal cell carcinoma (nccRCC): A single-arm, multicentre clinical trial
Wei Xue, Jiwei Huang
Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
#274MO
Mini Oral session: Genitourinary tumours
Sunday, December 8, 2024
9:42 – 9:47 AM Singapore Time
Stereotactic body radiation therapy followed by fruquintinib in combination with immunotherapy as third- and later-line treatment in metastatic colorectal cancer
Chen Zhang, Yi Wang
Ningbo No.2 Hospital, Ningbo, China
#81P
Poster Display: Gastrointestinal tumours, colorectal
Saturday, December 7, 2024
Results from FRONT study: A multicenter, randomized, open-label clinical trial of fruquintinib as maintenance therapy after 1L treatment in metastatic colorectal cancer (mCRC)
Tianshu Liu, Xiaojing Xu
Zhongshan Hospital Affiliated to Fudan University, Shanghai, China
#82P
Poster Display: Gastrointestinal tumours, colorectal
Saturday, December 7, 2024
Fruquintinib in combination with S-1 for ESCC patients after first-line immunotherapy failure: Update of dose-finding results
Lin Zhao, Ningning Li
Peking Union Medical College Hospital, Beijing, China
#194P
Poster Display: Gastrointestinal tumours, colorectal
Saturday, December 7, 2024
Abstract title
Presenter / Lead author
Presentation details
Efficacy and safety of concurrent bevacizumab in combination with standard radiotherapy and temozolomide followed by bevacizumab in combination with temozolomide and surufatinib in glioblastoma: A phase 2 clinical trial
Rongjie Tao, Hui Zhang
Shandong Cancer Hospital Affiliated to Shandong University, Jinan, China
#766P
Poster Display: General interest
Saturday, December 7, 2024